405P DKN-01 and atezolizumab as second or third-line therapy in advanced mismatch repair proficient (MMRp) oesophagogastric adenocarcinoma (OGA): WAKING trial
Anderley Gordon, E. Cartwright, Amina Tran et al. · Annals of Oncology · 2025
Cited by 1 works. doi:10.1016/j.annonc.2025.05.421 Open-access PDF